A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years. * Good general condition, with an ECOG Performance Status (PS) of 0-1. * Classified as China Liver Cancer Staging (CNLC) stage Ib (PS 0-2, Child-Pugh class A/B liver function, single tumor \>5 cm in diameter, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), IIa (PS 0-2, Child-Pugh class A/B liver function, 2-3 tumors with the largest diameter \>3 cm, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), IIb (PS 0-2, Child-Pugh class A/B liver function, ≥4 tumors regardless of diameter, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), or IIIa (PS 0-2, Child-Pugh class A/B liver function, any tumor status with radiologically visible vascular tumor thrombus but without extrahepatic metastasis). * No prior treatment for liver cancer. * Absence of distant metastasis, with the tumor anticipated to be completely resectable. * Patient provides written informed consent after being fully informed about the study. Exclusion Criteria: * Presence of severe impairment of heart, brain, lung, kidney, or other major organ function, severe concurrent infection, or other serious comorbid conditions (\> Grade 2 adverse events per CTCAE Version 4.03), rendering the patient unable to tolerate the treatment. * History of other malignancies. * History of allergy to related drugs. * History of organ transplantation. * Prior treatment for the tumor (including interferon). * Concurrent HIV infection. * History of drug or substance abuse. * Occurrence of gastrointestinal bleeding or cardiovascular/cerebrovascular events within approximately 30 days prior to treatment. * Pregnant or lactating women, or women of childbearing potential unwilling to use contraception. * Concurrent psychiatric disorders that prevent the patient from providing informed consent or interfere with receiving treatment. * Any other factors deemed by the investigator as likely to affect patient enrollment or the evaluation of results.